WO2007020502A3 - Cannabinoid receptor ligands and uses thereof - Google Patents

Cannabinoid receptor ligands and uses thereof Download PDF

Info

Publication number
WO2007020502A3
WO2007020502A3 PCT/IB2006/002172 IB2006002172W WO2007020502A3 WO 2007020502 A3 WO2007020502 A3 WO 2007020502A3 IB 2006002172 W IB2006002172 W IB 2006002172W WO 2007020502 A3 WO2007020502 A3 WO 2007020502A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor ligands
cannabinoid receptor
cannabinoid
mediation
animals
Prior art date
Application number
PCT/IB2006/002172
Other languages
French (fr)
Other versions
WO2007020502A2 (en
Inventor
Philip Albert Carpino
Mark Allen Sanner
Original Assignee
Pharmacia & Upjohn Co Llc
Philip Albert Carpino
Mark Allen Sanner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc, Philip Albert Carpino, Mark Allen Sanner filed Critical Pharmacia & Upjohn Co Llc
Publication of WO2007020502A2 publication Critical patent/WO2007020502A2/en
Publication of WO2007020502A3 publication Critical patent/WO2007020502A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein.
PCT/IB2006/002172 2005-08-16 2006-08-04 Cannabinoid receptor ligands and uses thereof WO2007020502A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70904505P 2005-08-16 2005-08-16
US60/709,045 2005-08-16

Publications (2)

Publication Number Publication Date
WO2007020502A2 WO2007020502A2 (en) 2007-02-22
WO2007020502A3 true WO2007020502A3 (en) 2007-04-19

Family

ID=37605675

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/002172 WO2007020502A2 (en) 2005-08-16 2006-08-04 Cannabinoid receptor ligands and uses thereof

Country Status (1)

Country Link
WO (1) WO2007020502A2 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008014199A2 (en) 2006-07-28 2008-01-31 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the cb2 receptor
AU2007283113A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
KR20090069318A (en) 2006-09-25 2009-06-30 베링거 인겔하임 인터내셔날 게엠베하 Compounds which modulate the cb2 receptor
TW200825067A (en) 2006-10-23 2008-06-16 Lilly Co Eli CB1 compounds
TW200831080A (en) 2006-12-15 2008-08-01 Irm Llc Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2008112674A1 (en) * 2007-03-12 2008-09-18 Irm Llc Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2008121065A1 (en) * 2007-03-30 2008-10-09 Astrazeneca Ab Novel pyrrolidine derivatives as antagonists of the chemokine receptor
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
JP5492092B2 (en) 2007-11-07 2014-05-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Compounds that modulate the CB2 receptor
ES2547880T3 (en) 2007-11-30 2015-10-09 Zynerba Pharmaceuticals, Inc. Tetrahydrocannabinol prodrugs, compositions comprising tetrahydrocannabinol prodrugs and methods for use thereof
PL2280961T3 (en) * 2008-04-22 2012-12-31 Lilly Co Eli 1,5-diphenyl-pyrrolidin-2-one compounds as cb-1 ligands
EP2278968A2 (en) 2008-04-22 2011-02-02 Eli Lilly And Company 1,5-diphenyl-pyrrolidin-2-one compounds as cb-1 ligands
AR072707A1 (en) 2008-07-09 2010-09-15 Sanofi Aventis HETEROCICLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION, DRUGS THAT UNDERSTAND THESE COMPOUNDS AND THE USE OF THEM
CA2730037A1 (en) * 2008-07-10 2010-01-14 Boehringer Ingelheim International Gmbh Sulfone compounds which modulate the cb2 receptor
NZ591111A (en) 2008-09-25 2013-08-30 Boehringer Ingelheim Int Sulfonyl compounds which selectively modulate the cb2 receptor
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
US8299103B2 (en) 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
WO2010147791A1 (en) 2009-06-16 2010-12-23 Boehringer Ingelheim International Gmbh Azetidine 2 -carboxamide derivatives which modulate the cb2 receptor
ES2443016T3 (en) 2009-08-26 2014-02-17 Sanofi New crystalline hydrates of heteroaromatic fluoroglycosides, pharmaceutical products comprising these compounds, and their use
JP2013505295A (en) 2009-09-22 2013-02-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Compound that selectively modulates CB2 receptor
EP2523936A1 (en) 2010-01-15 2012-11-21 Boehringer Ingelheim International GmbH Compounds which modulate the cb2 receptor
JP5746228B2 (en) 2010-03-05 2015-07-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Tetrazole compound that selectively modulates CB2 receptor
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
WO2012012307A1 (en) 2010-07-22 2012-01-26 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the cb2 rece
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
EP2683699B1 (en) 2011-03-08 2015-06-24 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
CN104788357B (en) * 2014-01-16 2017-06-06 韶远科技（上海)有限公司 The one class industrialized synthesis technique of chiral amino lactam compound

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003027069A1 (en) * 2001-09-24 2003-04-03 Bayer Pharmaceuticals Corporation Preparation and use of pyrrole derivatives for treating obesity
WO2004058249A1 (en) * 2002-12-24 2004-07-15 Astrazeneca Ab 1,5-diaryl-pyrrole-3-carboxamide derivatives and their use as cannabinoid receptor modulators

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003027069A1 (en) * 2001-09-24 2003-04-03 Bayer Pharmaceuticals Corporation Preparation and use of pyrrole derivatives for treating obesity
WO2004058249A1 (en) * 2002-12-24 2004-07-15 Astrazeneca Ab 1,5-diaryl-pyrrole-3-carboxamide derivatives and their use as cannabinoid receptor modulators

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; VAUGHAN, WYMAN R. ET AL: "2,3-Pyrrolidinediones. III. Tautomeric rearrangement", XP002416211, retrieved from STN Database accession no. 1954:18295 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; WASSERMAN, HARRY H. ET AL: "1,5-Diphenyl-2,3-pyrrolidinedione and related compounds", XP002416210, retrieved from STN Database accession no. 1962:416837 *
DUGAR, SUNDEEP ET AL: "Gamma-lactams and related compounds as cholesterol absorption inhibitors: homologs of the beta-lactam cholesterol absorption inhibitor SCH 48461", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS , 5(24), 2947-52 CODEN: BMCLE8; ISSN: 0960-894X, 1995, XP002415223 *
JOURNAL OF ORGANIC CHEMISTRY , 18, 405-21 CODEN: JOCEAH; ISSN: 0022-3263, 1953 *
JOURNAL OF ORGANIC CHEMISTRY , 27, 35-9 CODEN: JOCEAH; ISSN: 0022-3263, 1962 *
PELLETIER, JEFFREY C. ET AL: "Preparation of highly substituted .gamma.-lactam follicle stimulating hormone receptor agonists", BIOORGANIC & MEDICINAL CHEMISTRY , 13(21), 5986-5995 CODEN: BMECEP; ISSN: 0968-0896, 2005, XP002415222 *

Also Published As

Publication number Publication date
WO2007020502A2 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
WO2007020502A3 (en) Cannabinoid receptor ligands and uses thereof
MXPA05007938A (en) Cannabinoid receptor ligands and uses thereof.
TW200503723A (en) Cannabinoid receptor ligands and uses thereof
TW200510419A (en) Cannabinoid receptor ligands and uses thereof
MXPA05013294A (en) Cannabinoid receptor ligands and uses thereof.
MXPA05011362A (en) Cannabinoid receptor ligands and uses thereof.
TW200714603A (en) Acylaminobicyclic heteroaromatic compounds and uses thereof
MXPA05013282A (en) Pyrimidine derivatives as cannabinoid receptor ligands.
MXPA05011922A (en) Cannabinoid receptor ligands and uses thereof.
RS20050306A (en) Purine compounds and uses thereof as cannabinoid receptor ligands
MXPA05007562A (en) Pyrazolo`1,5-a!`1,3,5!triazine derivatives as cannabinoid receptor ligands.
UA74443C2 (en) 5-HT receptor ligands and their use
EA200501430A1 (en) Cannabinoid receptor ligands and their use
TW200716135A (en) Bicyclic pyrazolyl and imidazolyl compounds and uses thereof
WO2006004741A3 (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
WO2009002947A3 (en) Compounds and peptides that bind the trail receptor
MX2007005205A (en) Sulfonyl-substituted bicyclic compounds as modulators of ppar.
WO2006004684A8 (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
WO2007044085A3 (en) Heteroaryl compounds and their uses as therapeutic agents
MX2009005358A (en) 5-sulfanylmethyl-pyrazolo [1,5-a] pyrimidin-7-ol derivatives as cxcr2 antagonists.
TW200745043A (en) Substituted pyrazoline compounds, their preparation and use as medicaments
WO2007072201A3 (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
WO2009071689A3 (en) 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
WO2007022947A3 (en) 5-ring heteroaromatic compounds and their use as binding partners for 5-ht5 receptors
WO2005103052A8 (en) Pyrazolo [1,5-a] pyrimidin-7-one compounds and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06779949

Country of ref document: EP

Kind code of ref document: A2